Navigation Links
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
Date:5/14/2008

esults of Kosan's preclinical and clinical testing, including the risks that studies and trials may not demonstrate safety and efficacy sufficient to initiate clinical trials on the timing currently anticipated, or at all, continue clinical development, obtain the requisite regulatory approvals or result in a marketable product; the conduct of clinical trials; manufacturing; regulatory approval requirements and process; the effort and expense necessary for further development of Kosan's product candidates, including the costs of bortezomib; intellectual property matters, including Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and other risk factors are discussed under "Risk Factors" in Kosan's Annual Report on Form 10-K for the year ended December 31, 2007 and other periodic filings with the SEC. Kosan expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 MC Medical, a ... (MID), a Columbus, OH medical device ... the FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan in ... long-time experience and an extensive product portfolio in endoscopic surgery ...
(Date:8/22/2014)... 22, 2014  Mark Riccio, director of Cornell ... is using the online crowd-funding platform Kickstarter to ... to researchers and would-be superheros everywhere: "for FREE." ... YOU do if you had Superman,s X-ray vision?" ... explorers everywhere, from elementary through high school students, ...
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Republic, November 10, 2010, ... ... --> ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Nov. 10, 2010 A new initiative launched ... www.icsi.org ), a nonprofit, health care improvement ... more than $28 million annually, as well as ... The initiative is the first statewide diagnostic ...
Cached Medicine Technology:Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 2Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 3Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 4Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 5Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 6Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 7Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 8Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 9Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 2Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 3Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 4Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 5
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 ... penis sometimes comes into contact with the dirty water ... or the seat itself," said one of two inventors ... exposure to germs, we developed this protective device." , ... contacting unsanitary toilet surfaces, including the water, bowl and ...
(Date:8/23/2014)... On Monday, August 18th, The New ... suffered by Community Health Systems, which operates over 200 ... records containing Personally Identifiable Information (PII) like names, phone ... was engaged to investigate the incident, the belief is ... cyber attackers based in China, who they say are ...
(Date:8/23/2014)... California (PRWEB) August 23, 2014 Pixel Film ... themes, announced today the release of ProIntro Vol.3, a customizable ... a fresh and professional tile just by dragging ProIntro Vol.3 ... Studios. "ProIntro Vol.3 is a definite time saver and i ... intro pack with 30 beautifully designed titles made with Final ...
(Date:8/23/2014)... NC (PRWEB) August 23, 2014 Teen ... North Carolina. It’s no different in Wilmington, NC. Substance ... adults are falling victim to drug and alcohol dependency ... people are looking to overcome substance abuse, but don’t ... an adolescent treatment facility can be a challenge because ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is a ... years. He has recently announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ... 2014. , GoDaddy is a popular supplier of cheap ... hosting solutions at affordable rates. It offers three Linux ... plans depend on the length of the contract. The ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... life for those with tumors in bile duct, gall bladder ... chemotherapy drug to the treatment regimen of people with biliary ... research. , This type of cancer -- which occurs in ... to treat and often fatal. , "These are uncommon ...
... failed, trial results show , WEDNESDAY, April 7 (HealthDay ... second-round treatment for hepatitis cures about half the people ... research shows. , "This is the first large study ... said Dr. John G. McHutchison, associate director of the ...
... ... pre-event for the American Cancer Society’s highly anticipated “Starry Night Gala” that will occur ... ... 7, 2010 -- “An Evening of Hope” is the official pre-event for the ...
... ... ... with alarming new statistics and some hopeful highlights too. The bad news: according to the ... States will be diagnosed with autism spectrum disorder, or ASD. That’s up dramatically from ...
... sexually transmitted diseases , WEDNESDAY, April 7 (HealthDay News) ... to have multiple partners, researchers have found, and that ... they note. , "The United States has seen a ... sexually involved when they are just casually dating or ...
... Researchers from Boston University School of Medicine (BUSM) ... have discovered a new approach for identifying smokers at ... which appear in the April 7th issue of ... use a genomic approach to prevent lung cancer in ...
Cached Medicine News:Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 2Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 3Health News:New Drug Shows Promise for Curing Hepatitis C 2Health News:New Drug Shows Promise for Curing Hepatitis C 3Health News:"An Evening of Hope” - The Official Pre-Event for This Year's American Cancer Society Starry Night Gala 2Health News:Increase in Autism Rate and Treatments Focus of Autism Awareness Month 2Health News:Casual Sex Increasing in U.S. 2Health News:Researchers discover new approach for identifying smokers at highest risk for developing lung cancer 2
... HCS INTERACTANT is ... system. Financial applications include ... human resources and comprehensive ... financial applications are designed ...
... (Nitrogen) powder reagent once reconstituted offers the ... stability to help maximize laboratory productivity, minimize ... time. The patented technology of the Infinity ... shelf life and stability once reconstituted that ...
... The Infinity Triglycerides single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Triglycerides reagent provides a ...
... Creatinine single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... reagent provides a long shelf life ...
Medicine Products: